HOME About Santen News Investor Relations Products Careers Compliance  
A Clear Vision for Life, SANTEN PHARMACEUTICAL CO.,LTD  
Annual Report
Santen Brief History
Investigator-Initiated Trial Program Investigator-Initiated
Trial Program
Now Available
WE'VE MOVED: In order to accommodate our substantial expansion of the organization we have relocated our U.S. headquarters to Emeryville, California. This move will support our new vision and will enable us to continue to grow our tradition of developing novel pharmaceutical products that meet the needs of patients and physicians worldwide.

What’s New
Nov, 2011
Emeryville, CA

Santen Announces FDA Orphan Drug Status for Sirolimus (DE-­-109) .  [pdf: 58KB]

  
Sept, 2011
Emeryville, CA

Santen Announces EMA Orphan Drug Status For Sirolimus (DE-109) .  [pdf: 72KB]

  
July, 2011
Emeryville, CA

Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. of Osaka, Japan, announced the addition of four new employees to the Global Clinical and Medical Affairs Group.  [pdf: 99KB]

  
June, 2011
Napa, CA

Santen announces the initiation of a multinational Phase III Program evaluating sirolimus (DE-109) for the treatment of non infectious posterior uveitis  [pdf:118KB]

  
Apr, 2011
Napa, CA

Santen Inc. Announces Relocation of U.S. Corporate Headquarters [pdf:60KB]

  
 
Santen Inc. USA News News list
Santen Pharmaceutical Co., Ltd. Global News News list



 

Follow Us on Linkedin
Link to ParteneringWithSanten.com website